

16th INDUSTRY/ACADEMIA NEXT GENERATION PRECISION ONCOLOGY SYMPOSIUM

THURSDAY FEBRUARY 20, 2020 | GOLDBERG AUDITORIUM, MOORES CANCER CENTER | LA JOLLA, CALIFORNIA Organizers: Ida Deichaite, PhD & Scott Lippman, MD

	Organizers: Ida Deichaite, PhD & Scott Lippman, MD
8:00AM	Registration and Continental Breakfast
8:40AM	Organizer Welcome Ida Deichaite, PhD, Organizer, UC San Diego Moores Cancer Center
8:45AM	Director's Welcome: <i>Precancer 2020</i> Scott Lippman, MD, Director, UC San Diego Moores Cancer Center
8:55AM	The Emergence of a Pre-Cancer Genomics Atlas Ludmil Alexandrov, PhD, UC San Diego Moores Cancer Center
9:10AM	Session: Solid Tumors Chair: J. Silvio Gutkind, PhD, UC San Diego Moores Cancer Center
9:15AM	Targeting extrachromosomal DNA (ecDNA), a new approach to treating cancers with high copy number gene amplification Zachary Hornby, Boundless Bio
9:30AM	Platform Approach to Pancreatic Cancer Therapy Gregory Botta, MD, PhD, UC San Diego Moores Cancer Center
9:45AM	Pancreatic Cancer Organoids Enable Precision Medicine Herve Tiriac, PhD, UC San Diego Moores Cancer Center
10:00AM	The Pathology of RET-altered Lung and Thyroid Cancers Anthony Sireci, MD, & Cynthia Rubenstein, PhD, Loxo Oncology at Lilly
10:15AM	KRAS G12C Inhibition: Opportunities for intersection of targeted therapy and immune checkpoint modifiers
	James Christensen, PhD, Mirati Therapeutics
10:30AM	Session Q&A and Discussion
10:45AM	Break
10:55AM	Duane Roth Award Presentation Recipient Scott Gottlieb, MD, 23rd Commissioner of the FDA, AEI Resident Fellow, NEA Partner
	Keynote Presentation: Duane Roth Award Lecture Opportunities through public to advance the care of cancer patients Scott Gottlieb, MD, 23rd Commissioner of the FDA, AEI Resident Fellow, NEA Partner
12:00PM	Lunch & Poster Session
1:30PM	Session: Immuno-Oncology Chair: Ezra Cohen, MD, UC San Diego Moores Cancer Center
1:35PM	Enabling adoptive cellular therapy against natural ligands Stephen Schoenberger, PhD, La Jolla Institute for Immunology, SDPCI, UCSD
1:50PM	Patient Experience Tamara Strauss, Patient Advocate
2:00PM	Personalized NeoAg vaccines Aaron Miller, MD, PhD, UC San Diego Moores Cancer Center
2:15PM	Development of genetically engineered T cell products for cancer therapy Adrian Bot, MD, PhD, Kite, a Gilead Company
2:30PM	The Yin and Yang of CAR T: Reaching the Full Potential of Cell Therapy William Go, MD, PhD, A2 Biotherapeutics
2:45PM	Pluripotent Cell-Derived Engineered T and NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy Bob Valamehr, PhD, Fate Therapeutics
3:00PM	Session Q&A and Discussion
3:15PM	Break
3:30PM	Session: Hematology/Oncology Chair: Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center
3:35PM	State of the Art Experimental Models for Aggressive Multiple Myeloma Fotios Asimakopoulos, MD, PhD, UC San Diego Moores Cancer Center
3:50PM	Protein Neddylation: A New Target for Therapeutics in Acute Myeloid Leukemia Ronan Swords, MD, PhD, AbbVie
4:05PM	Precision Therapy of Relapsed or Refractory Epstein-Barr Virus-positive (EBV+) Aggressive B-cell, T-cell, and Hodgkin Lymphoma utilizing a combination of a novel oral agent to Induce Viral Transcription and the Oral Anti-viral, Valganciclovir Ivor Royston, MD, Viracta Therapeutics
4:20PM	Session Q&A and Discussion
4:35PM	Fireside Chat: Are we about to see the full value of diagnostics realized across drug development and patient care? Mike Pellini, MD, Section 32 Moderated by Ian Stone, CanaleComm
5:05PM	Closing Remarks Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center

Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center

Symposium Reception at Goldberg Auditorium Foyer

5:10PM